Lin v. Solta Medical, Inc.

District Court, N.D. California·Decided December 23, 2024·No. 4:21-cv-05062·Unknown

Opinion

Case No. 21-cv-05062-PJH Plaintiff,

v. ORDER RE PARTIES’ MOTIONS TO EXCLUDE OPINION TESTIMONY Re: Dkt. Nos. 112, 113, 116, 118, 119 Defendant. & 120

Before the court are (1) plaintiff’s motion to exclude expert opinion testimony of Dr. Stewart Wang (Dkt. 112); (2) plaintiff’s motion to exclude expert opinion testimony of Jay Bennett and Richard Malwitz (Dkt. 113); (3) defendant’s motion to exclude expert opinion testimony of Monica Ip (Dkt. 116); (4) defendant’s motion to exclude expert opinion testimony of Alan Schwartz (Dkt. 118); (5) defendant’s motion to exclude expert opinion testimony of Dr. Christine Lee (Dkt. 119); and (6) defendant’s motion to exclude expert opinion testimony of Boris Leschinsky (Dkt. 120). Although the parties filed the above motions in conjunction with defendant’s motion for summary judgment, this order addresses the admissibility of the challenged expert opinions for purposes of both the motion for summary judgment and trial. The order granting in part and denying in part defendant’s motion for summary judgment (Dkt. 155) did not rely on any of the opinions excluded by this order . These matters are fully briefed and suitable for decision without oral argument. relevant legal authority, and good cause appearing, the court hereby rules as follows. A. Legal Standard Federal Rule of Evidence 702 permits experts qualified by “knowledge, skill, experience, training, or education” to testify “in the form of an opinion or otherwise” based on “scientific, technical, or other specialized knowledge” if that “knowledge will help the trier of fact to understand the evidence or to determine a fact in issue”. Fed. R. Evid. 702. The proponent of expert testimony bears the burden of establishing by a preponderance of the evidence that the admissibility requirements are met. See id., Advisory Committee Notes. The trial court is obliged to exercise “a gatekeeping role” regarding the admission of expert scientific testimony under Rule 702. Daubert v. Merrell Dow Pharms., Inc., 509 U.S. 579, 597 (1993). Daubert requires a two-part analysis. First, the court must determine whether an expert's testimony reflects “scientific knowledge,” whether the findings are “derived by the scientific method,” and whether the work product is “good science”—in other words, whether the testimony is reliable and trustworthy. Id. at 590 & n.9, 593. Second, the court must determine whether the testimony is “relevant to the task at hand.” Id. at 597. First, scientific evidence is reliable if it is grounded in methods of science—the focus is on principles and methodology, not on conclusions. Metabolife Int'l, Inc. v. Wornick, 264 F.3d 832, 841 (9th Cir. 2001); see also Stilwell v. Smith & Nephew, Inc., 482 F.3d 1187, 1192 (9th Cir. 2007) (reliability is not determined based on the “correctness of the expert's conclusions but the soundness of his methodology”). In determining whether an expert's reasoning or methodology is scientifically valid, the district court can consider “many factors” (Daubert, 509 U.S. at 593–94), including “(1) whether the scientific theory or technique can be (and has been) tested; (2) whether the theory or technique has been subjected to peer review and publication; (3) whether a technique is generally accepted in the relevant scientific community.” Metabolife, 264 F.3d at 841. Nevertheless, depending on the type of expert testimony offered, these factors may not be appropriate to assess reliability. Kumho Tire Co. v. Carmichael, 526 U.S. 137, 152 (1999) (“the trial judge must have considerable leeway in deciding in a particular case how to go about determining whether particular expert testimony is reliable”). Other factors that might be considered to assess reliability include whether an expert has unjustifiably extrapolated from an accepted premise to an unfounded conclusion (see General Elec. Co. v. Joiner, 522 U.S. 136, 146 (1997) (“[N]othing in either Daubert or the Federal Rules of Evidence requires a district court to admit opinion evidence that is connected to existing data only by the ipse dixit of the expert. A court may conclude that there is simply too great an analytical gap between the data and the opinion proffered.”)), or whether an expert has adequately accounted for obvious alternative explanations (see Claar v. Burlington Northern R. Co., 29 F.3d 499, 502 (9th Cir. 1994); Carnegie Mellon Univ. v. Hoffmann–LaRoche, Inc., 55 F.Supp.2d 1024, 1034–35 (N.D. Cal. 1999) (methodology may not be reliable if an expert “fail[s] to address and exclude alternative explanations for the data on which he bases his findings” or “reject[s] studies reporting contrary empirical findings”)). The trial court should ensure the expert “employs in the courtroom the same level of intellectual rigor that characterizes the practice of an expert in the relevant field.” Kumho Tire, 526 U.S. at 152. The court should also consider whether an expert prepared his methodology for purposes of litigation or articulated the methodology before litigation and without any incentive to reach a particular outcome. See Daubert v. Merrell Dow Pharms., Inc., 43 F.3d 1311, 1317 (9th Cir. 1995). Second, expert testimony is relevant if the knowledge underlying it has a “valid . . . connection to the pertinent inquiry.” Daubert, 509 U.S. at 591–92. As Rule 702 requires, it must “help the trier of fact to understand the evidence or to determine a fact in issue.” relevance] for one purpose is not necessarily scientific validity for other, unrelated purposes.” Daubert, 509 U.S. at 591. B. Analysis 1. Plaintiff’s Motion to Exclude Opinion Testimony of Dr. Stewart Wang Plaintiff moves to exclude three of Dr. Wang’s four proffered opinions. Specifically, she seeks to exclude the following:

Opinion 1. Authenticity of the Ulthera and Thermage CPT systems used during the treatment of Ms. Lin has not been established.

Opinion 2. There is no available evidence whether the transducer (Ulthera) or the treatment tip (Thermage CPT) was defective or counterfeit.

Free access — add to your briefcase to read the full text and ask questions with AI

Lin v. Solta Medical, Inc., (N.D. Cal. 2024).

Lin v. Solta Medical, Inc. (Lin v. Solta Medical, Inc.) — published by Counsel Stack Legal Research, free access to 12M+ legal documents.

Related

Pacific Mutual Life Insurance v. Haslip
499 U.S. 1 (Supreme Court, 1991)
General Electric Co. v. Joiner
522 U.S. 136 (Supreme Court, 1997)
United States v. Roland A. Soulard
730 F.2d 1292 (Ninth Circuit, 1984)
Lisa Stilwell v. Smith & Nephew, Inc., a Corporation
482 F.3d 1187 (Ninth Circuit, 2007)
Avivi v. Centro Medico Urgente Medical Center
71 Cal. Rptr. 3d 707 (California Court of Appeal, 2008)
Voilas v. General Motors Corp.
73 F. Supp. 2d 452 (D. New Jersey, 1999)
Carnegie Mellon University v. Hoffmann-LaRoche, Inc.
55 F. Supp. 2d 1024 (N.D. California, 1999)
Borrayo v. Avery
2 Cal. App. 5th 304 (California Court of Appeal, 2016)
Stephen Wendell v. Glaxosmithkline LLC
858 F.3d 1227 (Ninth Circuit, 2017)
Westberry v. Gislaved Gummi AB
178 F.3d 257 (Fourth Circuit, 1999)
Clausen v. M/V New Carissa
339 F.3d 1049 (Ninth Circuit, 2003)